Epothilones and the next generation of phase III trials for prostate cancer.
Bhandari
Manish S
MS
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Hussain
Maha
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D034261:Epothilones / Q000008:administration & dosage / Q000627:therapeutic use*; D004961:Estramustine / Q000008:administration & dosage; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000627:therapeutic use
C478223:BMS 310705; D034261:Epothilones; D043823:Taxoids; D004961:Estramustine; C430592:ixabepilone; C093788:epothilone B